However, blood investigation results showed activation of cytotoxic T lymphocytes, suggesting that the combination of CHK1/2 inhibitors with ICIs could enhance the anti-tumor activity and reverse the tumor cells’ resistance to ICB therapy (Do et al., 2021). The gene discussed is CHEK1; the disease is neoplasm.